Please provide your email address to receive an email when new articles are posted on . Spevigo (spesolimab) reduced the risk for generalized pustular psoriasis flares by 84% over 48 weeks. Spevigo’s ...

The EFFISAYIL ON study demonstrated that IV spesolimab may be an effective rescue therapy for GPP patients on SC spesolimab who experience a GPP flare.

Please provide your email address to receive an email when new articles are posted on . 53.3% of 750 mg IV imsidolimab-treated patients achieved the primary endpoint vs. 13.3% of placebo. Imsidolimab ...

Treatment with spesolimab led to rapid clinical improvement in patients with generalized pustular psoriasis and showed a favorable safety profile.

Localized pustular psoriasis is a term that refers to a limited area of small pus-filled blisters on your skin, typically on your hands or feet. It is distinct from generalized pustular psoriasis (GPP ...

The US Food and Drug Administration (FDA) has approved spesolimab-sbzo, an interleukin (IL)-36 receptor antagonist, for the treatment of generalized pustular psoriasis (GPP) in adults and in pediatric ...

Credit: Boehringer Ingelheim. The approval was based on data from the phase 2 Effisayil-2 study which included patients 12 years of age and older and weighing at least 40kg with a history of at least ...

An international panel of more than 30 experts has developed a consensus definition and diagnostic criteria for generalized pustular psoriasis (GPP). The new definition, published in JAMA Dermatology, ...

Psoriasis is a chronic autoimmune condition that speeds up the skin cell cycle, leading to inflammation, scaling, and visible ...

WASHINGTON, Feb. 25, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics ...

A team from Nagoya University in Japan has identified previously unidentified gene variants that are associated with the development of generalized pustular psoriasis (GPP). The team's findings, ...